Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 28, 2026; 32(36): 120338
Published online Sep 28, 2026. doi: 10.3748/wjg.120338
Published online Sep 28, 2026. doi: 10.3748/wjg.120338
Letter to the Editor: Helicobacter pylori eradication restores aspirin responsiveness - a thromboinflammatory interpretation
Jian-Jiang Song, Shuai Liu, Department of Cardiology, The First People’s Hospital of Jiashan, Jiaxing 314100, Zhejiang Province, China
Ning Li, Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Yong-Wei Yu, Department of Intensive Care Unit, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Co-corresponding authors: Yong-Wei Yu and Shuai Liu.
Author contributions: Song JJ and Li N wrote the manuscript and performed literature collection. Yu YY and Liu S conceptualized and designed the study framework, critically revised the manuscript, and supervised the overall scientific content. Yu YY focused on the mechanistic interpretation and integration of thromboinflammatory pathways, whereas Liu S supervised the clinical relevance and overall academic direction of the manuscript. Both corresponding authors played important and indispensable roles in study design, scientific interpretation, and manuscript revision, and therefore qualify as co-corresponding authors. All listed authors have read and approved the final manuscript and consented to the submission.
AI contribution statement: Google Translate was used during manuscript preparation solely for language translation assistance. ChatGPT (Open AI) was used for limited grammar refinement and structural optimization of the text. In addition, AI-assisted tools were used only for preliminary conceptual layout reference during figure preparation. The final figure was manually created and revised by the authors, including modifications based on reviewer comments. The manuscript subsequently underwent professional language editing by Editage. No AI tool was involved in study design, data generation, data analysis, interpretation of results, formulation of conclusions, or reference generation. All AI-assisted outputs were critically reviewed, manually revised, and verified by the authors, who take full responsibility for the accuracy, originality, and integrity of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Yong-Wei Yu, Academic Fellow, Department of Intensive Care Unit, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Shangcheng District, Hangzhou 310003, Zhejiang Province, China. yuyongwei@zju.edu.cn
Received: February 24, 2026
Revised: April 15, 2026
Accepted: May 26, 2026
Published online: September 28, 2026
Processing time: 178 Days and 23.6 Hours
Revised: April 15, 2026
Accepted: May 26, 2026
Published online: September 28, 2026
Processing time: 178 Days and 23.6 Hours
Core Tip
Core Tip: Helicobacter pylori infection may influence cardiovascular outcomes beyond peptic ulcer disease, particularly in chronic aspirin users. Persistent infection can sustain a thromboinflammatory state that increases platelet turnover and reactivity, thereby weakening effective cyclooxygenase-1 inhibition and producing functional aspirin resistance. We propose that the apparent cardiovascular benefit after eradication may reflect pharmacologic resensitization rather than short-term vascular remodeling. This hypothesis-generating perspective links infection biology with antiplatelet pharmacodynamics and may help explain inter-individual variability in aspirin efficacy.